secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001193125-25-071389
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Verrica appoints Gavin Corcoran to board as Class I director
------------------------------------------------------------

- Dr. Corcoran appointed effective March 31, 2025; term expires at 2025 annual meeting.
- Granted option to purchase 17,502 shares at grant-date closing price; vests over 3 years.
- Receives $40,000 annual retainer; eligible for annual option of 20,000 shares.
- Currently Chief Development Officer of Formation Bio; former CMO of Allergan and Actavis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/0001193125-25-071389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/d906738d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-071389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer